STOCK TITAN

OptiNose, Inc. - $OPTN STOCK NEWS

Welcome to our dedicated page for OptiNose news (Ticker: $OPTN), a resource for investors and traders seeking the latest updates and insights on OptiNose stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OptiNose's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OptiNose's position in the market.

Rhea-AI Summary
Optinose (OPTN) to present company overview and business update at 35th Annual Piper Sandler Healthcare Conference on November 29, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences
-
Rhea-AI Summary
Optinose (NASDAQ:OPTN) reports Q3 2023 XHANCE net revenue of $19.8 million, expects net revenue for 2023 to be between $66.0 to $70.0 million. The company's operating efficiency improved as SG&A and R&D expenses decreased by 33%. PDUFA goal date for XHANCE Chronic Rhinosinusitis sNDA is December 16, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
-
Rhea-AI Summary
Optinose to report Q3 2023 financial results and corporate updates on November 9, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
Rhea-AI Summary
Optinose to present at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.9%
Tags
-
Rhea-AI Summary
Optinose, a pharmaceutical company focused on ENT and allergy specialists, reported preliminary net product revenue of $19.5 million for Q2 2023, exceeding expectations. The company plans to update its full-year 2023 XHANCE net revenue guidance on August 10. A conference call to discuss financial results and corporate updates will be held on the same day at 8:00 a.m. Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.45%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.43%
Tags
OptiNose, Inc.

Nasdaq:OPTN

OPTN Rankings

OPTN Stock Data

133.95M
82.34M
8.97%
77.6%
2.76%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
YARDLEY

About OPTN

optinose, inc., established in 2010 and headquartered in yardley, pennsylvania, is a publicly traded, global specialty pharmaceutical company focused on serving the needs of patients cared for by ent and allergy specialists. our team of kind, passionate, innovative people is building a new kind of organization without the encumbrances of a company with legacy systems and beliefs. we are unified by a shared mission: to improve lives. we do this while also creating great value for the healthcare system and great outcomes for our stakeholders. as innovators in every aspect of our work, we pursue faster and less costly product development, explore evolving commercial business models, and actively seek innovative ways to be more effective and efficient in all areas of the business. we operate with an overarching commitment to doing what is right. we are committed to working together as a team that chooses to live every day by core company values that guide our daily behaviors, creating a fo